Delphine Guyon-Gellin

Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine

G. Leroux-Roels, P. Moris, I. Leroux-Roels, 2022, Frontiers in Immunology.

OVX836 Heptameric Nucleoprotein Vaccine Generates Lung Tissue-Resident Memory CD8+ T-Cells for Cross-Protection Against Influenza

J. Marvel, Y. Leverrier, Fergal Hill, 2021, Frontiers in Immunology.

OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model

F. Salguero, T. Courant, F. Boué, 2023, Frontiers in Immunology.